Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
Department of Vascular Medicine, Klinikum Darmstadt GmbH, Darmstadt, Germany.
Hamostaseologie. 2020 Dec;40(5):572-590. doi: 10.1055/a-1132-0750. Epub 2020 Jun 26.
Venous thromboembolism (VTE) is a major cause of maternal morbidity during pregnancy and the postpartum period. Because there is a lack of adequate study data, management strategies for the prevention of VTE during pregnancy have mainly been deduced from case-control and observational studies and extrapolated from recommendations for non-pregnant patients. The decision for or against pharmacologic thromboprophylaxis must be made on an individual basis weighing the risk of VTE against the risk of adverse side effects such as severe bleeding complications. A comprehensive, multidisciplinary approach is often essential as the clinical scenario is made more complex by the specific obstetric context, especially in the peripartum period. As members of the Working Group in Women's Health of the Society of Thrombosis and Haemostasis (GTH), we summarize the evidence from the available literature and aim to establish a more uniform strategy for VTE risk assessment and thromboprophylaxis in pregnancy and the puerperium. In this document, we focus on women with hereditary thrombophilia, prior VTE and the use of anticoagulants that can safely be applied during pregnancy and the lactation period.
静脉血栓栓塞症(VTE)是妊娠期和产后期间产妇发病率的主要原因。由于缺乏足够的研究数据,妊娠期 VTE 预防的管理策略主要是从病例对照和观察性研究中推断出来的,并从非妊娠患者的建议中推断出来。是否选择药物血栓预防必须根据个人情况权衡 VTE 的风险与严重出血并发症等不良副作用的风险来决定。由于特定的产科背景使临床情况更加复杂,通常需要综合多学科方法,尤其是在围产期。作为血栓形成和止血学会(GTH)妇女健康工作组的成员,我们总结了现有文献中的证据,并旨在为妊娠期和产褥期的 VTE 风险评估和血栓预防建立更统一的策略。在本文件中,我们重点关注遗传性血栓形成倾向、既往 VTE 和使用可在妊娠期和哺乳期安全应用的抗凝剂的妇女。